Poly(Lactic-co-Glycolic Acid) Applications and Future Prospects for Periodontal Tissue Regeneration
Sun, X.; Wu, G.; Xu, C.; Ye, Q.; Wang, C
Summary
Periodontitis causes irreversible destruction of periodontal tissues, and regeneration requires biomaterials with suitable mechanical, degradation, and biological properties. PLGA is attractive for periodontal regeneration because of its biocompatibility, tunable degradation, and processability, but its hydrophobicity and limited bioactivity restrict performance. This review summarizes PLGA properties and progress as barrier membranes, bone. Rhesus monkey intrabony defects: PLGA membrane vs flap only: new cementum 2.74 vs 0.20 mm, new bone 2.64 vs 0.19 mm, connective tissue adhesion 2.80 vs 0.20 mm. - Class II furcation defects: PLGA membranes gave 250–350%.
Keywords
PLGADrug deliveryPolymericHydrogelsNanoparticlesBiomaterialsNanocarriers
Purpose: Periodontitis causes irreversible destruction of periodontal tissues, and regeneration requires biomaterials with suitable mechanical, degradation, and biological properties. PLGA is attractive for periodontal regeneration because of its biocompatibility, tunable degradation, and processability, but its hydrophobicity and limited bioactivity restrict performance. This review summarizes PLGA properties and progress as barrier membranes, bone grafts, and drug delivery carriers for periodontal tissue regeneration.
Hypothesis: This is a review article and does not test a single formal hypothesis. Its central premise is that PLGA, despite limitations such as hydrophobicity and suboptimal bioactivity, can be a good candidate material for periodontal regenerative medicine, especially when modified or combined with other materials to improve biological performance.
Aims: Summarize the physicochemical properties, biocompatibility, and biodegradability of PLGA relevant to periodontal therapy. - Review preclinical and clinical applications of PLGA as guided tissue regeneration (GTR) barrier membranes. - Review PLGA-based bone scaffolds and bone grafting materials for periodontal defects. - Review PLGA-based drug delivery systems for growth factors and antimicrobial drugs. - Discuss future directions, including surface modification, hydrophobicity modification, bioactivity improvement, and PLGA-based cell engineering.
Delivery system: Polymer: Poly(lactic-co-glycolic acid) (PLGA), a synthetic aliphatic copolymer of lactic acid (LA) and glycolic acid (GA). - Forms: Membranes/meshes, scaffolds, hydrogels, nanoparticles, microparticles, sponges, nanofibers, and gels. - Payloads: Growth factors (PDGF, BMPs, rhGDF-5), antimicrobial drugs (tetracycline, doxycycline, metronidazole), and cells (periodontal ligament cells, cementoblasts, adipose-derived stromal cells). - Target application: Periodontal tissue regeneration, including GTR/GBR, bone grafting, and local drug delivery. - Key properties: Tunable LA/GA ratio, molecular weight, crystallinity, degradation rate, mechanical strength, and FDA approval for human use.
Approach: Review of preclinical and clinical literature. Animal models include rhesus monkeys, dogs, rats, and mice. Human clinical studies include intrabony defects and Class II furcation defects. Commercial products are summarized. No new primary experiments are reported.
Key methods: Histological assessment of new cementum, new bone, connective tissue adhesion, and junctional epithelium. - Clinical measurements: pocket probing depth reduction, clinical attachment level gain, gingival margin recession, and radiologic bone fill. - Material characterization: SEM, degradation, drug release kinetics, mechanical properties. - Cell assays: proliferation, osteogenic differentiation, and cell attachment.
Key results: Rhesus monkey intrabony defects: PLGA membrane vs flap only: new cementum 2.74 vs 0.20 mm, new bone 2.64 vs 0.19 mm, connective tissue adhesion 2.80 vs 0.20 mm. - Class II furcation defects: PLGA membranes gave 250–350% more gain in new cementum, bone, and connective tissue adhesion than flap surgery. - Human clinical trial: Tonetti et al.: clinical attachment level gain 3.04 vs 2.18 mm for PLGA membrane vs flap only. - Aimetti et al.: pocket probing depth reduction 3.44 vs 2.39 mm, radiologic bone fill 2.13 vs 1.05 mm for PLGA vs flap only. - Tetracycline-loaded PLGA membranes in dogs: new cementum 2.97 vs 1.48 mm and new bone 2.88 vs 1.46 mm vs sham surgery. - rhGDF-5-loaded PLGA hydrogels: significantly more bone regeneration, cementum formation, and bone maturation than sham surgery.
Interpretation: PLGA has excellent biocompatibility, tunable degradation, and versatile processability, making it suitable for periodontal regeneration as barrier membranes, bone grafts, and drug delivery systems. Pure PLGA has poor hydrophilicity and limited bioactivity, but surface modification, blending, copolymerization, and bioactive molecule loading can overcome these limitations. PLGA-based constructs are promising for periodontal tissue regeneration, and future multifunctional devices should mimic biomimetic repair mechanisms while preventing unwanted fast migration of gingival fibroblastic cells.
Limitations: This is a review, not a primary study; no new experimental data or meta-analysis. - Pure PLGA is hydrophobic, has low cell affinity, and lacks natural recognition sites for cell attachment. - Clinical performance is often comparable, not always superior, to non-resorbable ePTFE or collagen membranes. - Several clinical studies have small sample sizes and high subject variability. - Long-term stability data are limited; one 10-year study showed maintained benefits but no statistically significant advantage over ePTFE. - Modification strategies are mostly preclinical and require further validation.
Related articles
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programs with pharma, biotech and academic groups — from target selection through GMP supply.